Intellia Therapeutics, Inc(NASDAQ:NTLA) 
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which i...
Website: http://www.intelliatx.com
Founded: 2014
Full Time Employees: 270
CEO: John Leonard
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 6.83
H 6.91
L 6.43
C 6.63
V 4,803,391
10EMA 6.63
20EMA 6.63
60EMA 6.63
120EMA 6.63
250EMA 6.63